UB Paderborn / Katalog / Suche / in CDI

Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAF V600 -positive melanoma: Interim analysis of the ImmunoCobiVem study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9548-9548

2022

Link zum Volltext

Verfügbarkeit prüfen

Acupuncture for the Treatment of Atopic Itch - A Systematic Literature Review

Herbst, Rudolf Alexander

2018

Link zum Volltext
ProQuest

Unilateral laterothoracic exanthem (asymmetrical periflexural exanthem of childhood): Report of an adult patient

Journal of the American Academy of Dermatology, 1997-09, Vol.37 (3), p.484-485

1997

Link zum Volltext

Verfügbarkeit prüfen

Alkaptonuric ochronosis: Report of two affected brothers

Journal of the American Academy of Dermatology, 1997-08, Vol.37 (2), p.305-307

1997

Link zum Volltext

Verfügbarkeit prüfen

Unilateral laterothoracic exanthem (asymmetrical periflexural exanthem of childhood): Report of an adult patient

Journal of the American Academy of Dermatology, 1997-09, Vol.37 (3), p.484-485

1997

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet (British edition), 2020-05, Vol.395 (10236), p.1558-1568

2020

Link zum Volltext

Verfügbarkeit prüfen

Diverse sulfate-reducing bacteria of the Desulfosarcina/Desulfococcus clade are the key alkane degraders at marine seeps

The ISME Journal, 2014-10, Vol.8 (10), p.2029-2044

2014

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

The Lancet (British edition), 2022-10, Vol.400 (10358), p.1117-1129

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma

PloS one, 2015-03, Vol.10 (3), p.e0118564

2015

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS

Acta dermato-venereologica, 2022-04, Vol.102, p.adv00695-adv00695

2022

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

The Lancet (British edition), 2023-09, Vol.402 (10404), p.798-808

2023

Link zum Volltext

Verfügbarkeit prüfen

Salvage therapy after failure from anti-PD-1 single agent treatment: A Study by the German ADOReg melanoma registry

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9505-9505

2019

Link zum Volltext

Verfügbarkeit prüfen

Characterisation and outcome of RAC1 mutated melanoma

European journal of cancer (1990), 2023-04, Vol.183, p.1-10

2023

Link zum Volltext

Verfügbarkeit prüfen

Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma: A prospective multicenter DeCOG study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9568-9568

2021

Link zum Volltext

Verfügbarkeit prüfen

PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma

European journal of cancer (1990), 2018-01, Vol.88, p.67-76

2018

Link zum Volltext

Verfügbarkeit prüfen

Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG

Journal for immunotherapy of cancer, 2023-04, Vol.11 (4), p.e005828

2023

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAF V600 -positive melanoma: Interim analysis of the ImmunoCobiVem study

Acupuncture for the Treatment of Atopic Itch - A Systematic Literature Review

Unilateral laterothoracic exanthem (asymmetrical periflexural exanthem of childhood): Report of an adult patient

Alkaptonuric ochronosis: Report of two affected brothers

Unilateral laterothoracic exanthem (asymmetrical periflexural exanthem of childhood): Report of an adult patient

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

Diverse sulfate-reducing bacteria of the Desulfosarcina/Desulfococcus clade are the key alkane degraders at marine seeps

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma

Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma

Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma

Salvage therapy after failure from anti-PD-1 single agent treatment: A Study by the German ADOReg melanoma registry

MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma – An evaluation of the multicenter prospective skin cancer registry ADOREG

NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors

Characterisation and outcome of RAC1 mutated melanoma

Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma: A prospective multicenter DeCOG study

TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy

Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study

TERT promoter mutations are associated with longer progression-free and overall survival in BRAF-mutant melanoma patients receiving BRAF and MEK inhibitor therapy

PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma

Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG

Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM

Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIMResearch in context

Suchergebnisse filtern